curasan AG commences operations in the European market with the appointment of a marketing expert

Kleinostheim, 15.02.2012 – curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8), created a new post on 1st February 2012 in relation to the active expansion of its European sales network in the fields of Orthopaedics and trauma surgery. Mr. Lee McCann BSc Business Administration (North West University of Applied Science, London, U.K.), will be operating as the organisation’s International Sales Director for Orthobiologics with immediate effect.

Apart from possessing a sound knowledge of the Orthobiologics market, Mr. McCann has considerable experience in international sales and corporate development to take on the new challenge. This has been proven following his work in these segments as the Business Development Manager, Europe for biomaterials in spine surgery and as an International Marketing Manager for such market-leading competitors as Orthovita Inc., Malvern, PA, USA, and Apatech Ltd., London, U.K. In the process, he has successfully set up an international sales network for medical products and, as a consequence, motivated and supported the distributors.

"We will cooperate with different partners for sales in the most important European countries. In order to choose the right companies and sign contracts with them we require special experience" explained Hans Dieter Rössler, Chairman and CEO of curasan AG. "In Lee McCann, we have appointed a professional who has already achieved this both successfully and repeatedly in the Orthopaedics market. Based on his specific knowledge of the industry and international experience, work on sales and marketing activities in the most important European markets should begin in the current year".

Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading companies in the field of regenerative medicine especially in bone and tissue regeneration. The company has developed a future-oriented product pipeline in synthetic bone substitutes and bone regeneration material. Some of these various new developments are ready for market rollout. Further products are about to follow within the next two years. These biomaterials will be distributed in different submarkets by well-positioned contractual partners. www.curasan.com

Press Contact:
curasan AG
Andrea Weidner
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
andrea.weidner@curasan.de
www.curasan.de

fr financial relations gmbh
Jörn Gleisner
Tel. +49 (0)69 95 90 83 20
Fax +49 (0)69 95 90 83 99
j.gleisner@financial-relations.de

This release was published on openPR.